NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

MBRX

Moleculin Biotech Inc

Jul 09 • 11:26AM ET

0.5807

Dollar change +0.0593
Percentage change 11.37	%

Healthcare • Biotechnology • USA • NASD

Peers: TGTX FATE AFMD KPTI AVIR ADAP IMMP XFOR BYSI HOOK

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.80	Insider Own	8.74%	Shs Outstand	24.10M	Perf Week	78.95%
Market Cap	14.00M	Forward P/E	-	EPS next Y	-1.36	Insider Trans	81.52%	Shs Float	21.99M	Perf Month	-13.33%
Enterprise Value	6.73M	PEG	-	EPS next Q	-0.40	Inst Own	6.13%	Short Float	8.79%	Perf Quarter	-26.32%
Income	-23.23M	P/S	-	EPS this Y	75.21%	Inst Trans	0.99%	Short Ratio	0.53	Perf Half Y	-67.56%
Sales	0.00M	P/B	195.52	EPS next Y	13.19%	ROA	-89.59%	Short Interest	1.93M	Perf YTD	-65.84%
Book/sh	0.00	P/C	1.81	EPS next 5Y	42.60%	ROE	-214.79%	52W High	4.71 -87.66%	Perf Year	-83.36%
Cash/sh	0.32	P/FCF	-	EPS past 3/5Y	10.68% 26.36%	ROIC	-6312.23%	52W Low	0.25 132.28%	Perf 3Y	-97.37%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	23.67% 15.92%	Perf 5Y	-99.33%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	55.36%	Oper. Margin	-	ATR (14)	0.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.35	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	54.03	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.35	EPS Q/Q	65.82%	SMA20	26.59%	Beta	1.26	Target Price	7.00
Payout	-	Debt/Eq	11.25	Sales Q/Q	-	SMA50	-22.04%	Rel Volume	24.36	Prev Close	0.52
Employees	17	LT Debt/Eq	8.25	Earnings	May 13 AMC	SMA200	-62.50%	Avg Volume	3.65M	Price	0.58
IPO	Jun 02, 2016	Option/Short	No / Yes	EPS/Sales Surpr.	-24.32% -	Trades		Volume	29,593,023	Change	11.37%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-09-25	Resumed	H.C. Wainwright	Buy	$4
Feb-12-25	Downgrade	Maxim Group	Buy → Hold
Jul-18-22	Resumed	Oppenheimer	Outperform	$14

Today 08:35AM	Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans (GlobeNewswire) +11.37%
Jun-21-25 09:25AM	Moleculin Biotech prices 16.08M shares at 37c in public offering (TipRanks)
Jun-20-25 09:20AM	Moleculin Announces $5.9 Million Public Offering (GlobeNewswire) -54.20%
Jun-18-25 07:45AM	Moleculin Participates in Virtual Investor "What This Means" Segment (GlobeNewswire) -12.46%
07:30AM	Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML (GlobeNewswire)
09:20AM	Loading…
Jun-12-25 09:20AM	Moleculin Biotech announces What This Means virtual investor segment (TipRanks)
Jun-11-25 09:15AM	Moleculin Participates in Virtual Investor "What This Means" Segment (GlobeNewswire)
Jun-05-25 08:00AM	Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107) (GlobeNewswire)
Jun-04-25 08:45AM	Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) (GlobeNewswire) -19.83%
May-15-25 03:12AM	Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com) -8.17%
May-14-25 07:30AM	Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -7.20%
May-13-25 05:19AM	EMA approves Moleculins application for Phase IIb/III AML trial (Clinical Trials Arena)
May-12-25 08:40AM	Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial (GlobeNewswire)
May-07-25 09:00AM	Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast (GlobeNewswire)
May-06-25 09:00AM	Moleculin Announces World Health Organization Approval of "naxtarubicin" as International Non-Proprietary Name for Annamycin (GlobeNewswire)
08:45AM	Loading…
May-05-25 08:45AM	Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents (GlobeNewswire)
Apr-29-25 08:35AM	Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer (GlobeNewswire)
Apr-17-25 08:30AM	Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire)
Apr-02-25 08:41AM	Moleculin Biotech doses first patient in Phase 3 MIRACLE trial (TipRanks)
05:51AM	Moleculin Biotech begins dosing subjects in combination therapy trial for AML (Clinical Trials Arena)
Apr-01-25 09:55AM	Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now (Zacks)
08:30AM	Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial (GlobeNewswire)
Mar-26-25 12:00PM	All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy (Zacks) -6.96%
Mar-25-25 03:00AM	Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ... (GuruFocus.com) +8.49%
01:38AM	Q4 2024 Moleculin Biotech Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-24-25 10:50AM	Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript (SeekingAlpha)
07:05AM	Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-19-25 08:05AM	Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast (GlobeNewswire)
Mar-11-25 08:45AM	Moleculin Biotech, Inc. Participates in the Virtual Investor 'Top 5 for '25' On-Demand Conference (PR Newswire)
Mar-10-25 08:45AM	Moleculin to Present at the 37th Annual ROTH Conference (PR Newswire)
08:30AM	Loading…
Mar-06-25 08:30AM	Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity (PR Newswire) -5.17%
Mar-03-25 08:30AM	Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium (PR Newswire) -10.85%
Feb-25-25 12:35PM	Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules (PR Newswire) +20.56%
Feb-13-25 01:19PM	Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday? (Benzinga) +202.38%
01:05PM	Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds (PR Newswire)
09:25AM	Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML) (PR Newswire)
Feb-12-25 10:25AM	Moleculin Biotech gains approval for enrolment in trial of AML therapy in Ukraine (Clinical Trials Arena) -17.24%
Feb-11-25 08:40AM	Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial (PR Newswire) -27.91%
Jan-27-25 08:30AM	Moleculin Participates in Virtual Investor 'What This Means' Segment (PR Newswire)
Jan-08-25 08:30AM	Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 and 2026 (PR Newswire)
08:30AM	Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026 (PR Newswire)
Dec-11-24 08:00AM	Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model (PR Newswire) +14.72%
Nov-18-24 08:15AM	New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML (PR Newswire) -7.01%
Nov-14-24 08:15AM	Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025 (PR Newswire) +23.11%
Nov-12-24 10:59PM	Moleculin Biotech Reports Financial Highlights and Future Plans (TipRanks) +5.18%
08:00AM	Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML) (PR Newswire)
Nov-11-24 11:19PM	Q3 2024 Moleculin Biotech Inc Earnings Call (Thomson Reuters StreetEvents)
07:05AM	Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Nov-05-24 09:00AM	Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast (PR Newswire)
Nov-04-24 08:30AM	Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin (PR Newswire)
Oct-18-24 08:57AM	Moleculin Biotech Highlights Annamycins AML Treatment Potential (TipRanks) +9.53%
Oct-17-24 08:40AM	Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available (PR Newswire)
Oct-09-24 05:02PM	Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ... (GuruFocus.com)
Oct-07-24 08:30AM	Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024 (PR Newswire) +6.36%
Oct-04-24 09:00AM	Moleculin to Present at Two Upcoming Investor Conferences (PR Newswire)
Sep-23-24 08:00AM	Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma (PR Newswire) +14.35%
Sep-16-24 08:30AM	Moleculin Participates in Virtual Investor 'What this Means' Segment (PR Newswire)
Sep-09-24 08:15AM	Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma (PR Newswire)
Sep-03-24 09:15AM	Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire)
Aug-26-24 08:30AM	Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar (PR Newswire) +6.69%
Aug-19-24 04:05PM	Moleculin Announces Closing of up to $16.5 Million Public Offering (PR Newswire) +7.08%
Aug-16-24 08:00AM	Moleculin Announces Pricing of up to $16.5 Million Public Offering (PR Newswire) +9.42%
Aug-14-24 08:05AM	Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire) +6.38%
Aug-05-24 09:05AM	Moleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ET (PR Newswire) -6.95%
Aug-01-24 08:30AM	Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial (PR Newswire) -27.94%
Jul-10-24 08:30AM	Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML (PR Newswire)
Jun-17-24 08:00AM	Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024 (ACCESSWIRE)
Jun-14-24 08:00AM	Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial (PR Newswire)
Jun-12-24 09:00AM	Moleculin to Present at the Virtual Investor Pitch Conference (PR Newswire)
Jun-10-24 08:00AM	JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024 (ACCESSWIRE)
Jun-05-24 08:55AM	Moleculin to Participate in the Virtual Investor Lunch Break Series (PR Newswire) +7.95%
May-16-24 08:32AM	Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress (PR Newswire)
06:22AM	Moleculin begins NIH-funded Phase II glioblastoma treatment trial (Clinical Trials Arena)
May-15-24 08:38AM	Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06) (PR Newswire)
May-14-24 03:00AM	Moleculin Biotech Inc (MBRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ... (GuruFocus.com)
May-13-24 07:30AM	Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-10-24 09:52PM	MBRX Stock Earnings: Moleculin Biotech Beats EPS for Q1 2024 (InvestorPlace)
May-09-24 08:30AM	Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin (PR Newswire)
May-08-24 08:45AM	Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast (PR Newswire) -7.66%
May-07-24 08:55AM	Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data (PR Newswire)
May-02-24 09:00AM	Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024 (PR Newswire)
May-01-24 08:50AM	Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin (PR Newswire)
Apr-25-24 09:45AM	Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor 'What This Means' Segment Hosted by JTC Team (ACCESSWIRE)
Apr-18-24 08:30AM	European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) (PR Newswire) +5.69%
Apr-10-24 08:30AM	Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties (PR Newswire)
Mar-28-24 10:45AM	Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference (PR Newswire) +6.68%
Mar-27-24 09:25AM	Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity (PR Newswire) +18.38%
09:05AM	Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML (PR Newswire)
Mar-26-24 08:36AM	Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call Transcript (Insider Monkey) -10.86%
Mar-25-24 07:30AM	Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial (PR Newswire) -7.97%
Mar-22-24 08:52PM	MBRX Stock Earnings: Moleculin Biotech Reported Results for Q4 2023 (InvestorPlace) -13.96%
05:31PM	Moleculin Biotech Inc Reports Fiscal Year 2023 Financial Results (GuruFocus.com)
04:05PM	Moleculin Reports Full Year 2023 Financial Results (PR Newswire)
Mar-20-24 07:30AM	Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast (PR Newswire) -19.70%
Mar-19-24 04:30PM	Moleculin Announces Reverse Stock Split (PR Newswire)
Mar-12-24 09:05AM	Moleculin to Present at the 36th Annual ROTH Conference (PR Newswire) -11.22%
Jan-24-24 08:50AM	Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3 (PR Newswire) +11.08%
Dec-20-23 09:16PM	Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market (PR Newswire)
Dec-11-23 08:50AM	Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual Meeting (PR Newswire) -8.07%
Nov-14-23 01:46PM	Moleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2023 Earnings Call Transcript (Insider Monkey)

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe in July 2015 and is headquartered in Houston, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Foster Jonathan P.	Chief Financial Officer	Jun 23 '25	Buy	0.37	270,270	100,000	287,587	Jun 23 04:35 PM
KLEMP WALTER V	CEO and President	Jun 23 '25	Buy	0.37	675,675	250,000	743,607	Jun 23 04:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MBRX

Moleculin Biotech Inc

Upgrade your FINVIZ experience